Clinical trials: Autoimmune Disorder
Multiple Sclerosis
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
The primary objective is to assess the effect of treatment with glatiramer acetate (GA) compared to placebo on the time to conversion to CDMS, as determined by Poser criteria (the occurrence of the second clinical attack) during…
- Trial name
- PreCISe (NCT00666224)
- Testing
- Glatiramer Acetate (DB), Glatiramer Acetate (OL)
- Volunteers
- 481 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Systemic Lupus Erythematosus
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients.
- Trial name
- DIVERT (NCT05306873)
- Testing
- Mycophenolate Mofetil, Voclosporin
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus
Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM
This study evaluates early initiation of continuous subcutaneous insulin infusion (CSII) therapy in young children using a novel delivery method in the form of a self-contained, lightweight, and disposable insulin pump unit…
- Trial name
- NCT00476788
- Testing
- Omnipod Insulin Management System
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Type 1 Diabetes Mellitus
Rituximab in New Onset Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
- Trial name
- TN05 (NCT00279305)
- Testing
- Anti-CD20 (rituximab)
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 87 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes, Adherence, Patient
Diabetes Journey: An Adolescent Adherence Barriers Intervention
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a web-based intervention addressing adherence barriers in adolescents with T1D.
- Trial name
- NCT04404556
- Testing
- Diabetes Journey, Enhanced Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 195 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Diabetes Mellitus, Type 1
Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents
The purpose of this study is to use a closed-loop Control-to-Range (CTR) system in adolescents with type 1 diabetes in an outpatient setting, and to evaluate the CTR system's ability to significantly improve blood glucose levels…
- Trial name
- NCT01890954
- Testing
- Diabetes Assistant (DiAs)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Additional Insulin for Fat and Protein in Children With Diabetes Study
The aims of the study are to see if additional insulin doses for the fat and protein in a meal, given at different times, improve blood glucose levels and are safe and acceptable to children with Type 1 diabetes using multiple…
- Trial name
- NCT02680054
- Testing
- Insulin, Asp(B28)-
- Where
- 2 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Oxford University Hospitals NHS Trust
Rheumatoid Arthritis
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT01373151
- Testing
- BMS-945429, Methotrexate
- Where
- 100 sites in United States, Argentina and 17 more
- Volunteers
- 418 people
- Sponsor
- CSL Behring
Degenerative Joint Disease, Congenital Deformity
Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
STUDY OBJECTIVES: To demonstrate equivalent clinical and radiologic outcomes as "gold standard" (Autologous Bone Graft) in a representative clinical model (hindfoot fusions) STUDY HYPOTHESIS: Augment® Injectable is an equivalent…
- Conditions
- Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis
- Trial name
- NCT01305356
- Testing
- Augment® Injectable Bone Graft, Autologous bone graft
- Where
- 25 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- BioMimetic Therapeutics
Autoimmune Disorders
A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
The purpose of this study is to test the oral tolerance of Keyhole Limpet Hemocyanin (KLH) and to determine if Immucothel by itself is strong enough to trigger the immune response.
- Trial name
- NCT01489956
- Testing
- Immucothel Alone (Part A), Immucothel+Montanide (Part A), Immucothel Alone or Immucothel+Montanide (Part B)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
Natural history research in Multiple Sclerosis (MS) suggests that risk of relapses and new Magnetic Resonance Imaging (MRI) changes diminish significantly as people age, especially in MS patients 55 or older.
- Trial name
- DISCOMS (NCT03073603)
- Testing
- Discontinuation of disease modifying therapy, Standard of Care
- Where
- 19 sites in United States
- Volunteers
- 259 people
- Sponsor
- University of Colorado, Denver
Rheumatoid Arthritis
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
The purpose of this 2 phased, open-label study is to compare the safety and efficacy of etanercept with conventional Disease Modifying Antirheumatic Drug (DMARD) therapy in Latin American subjects with moderate to severe…
- Trial name
- NCT00848354
- Testing
- Phase 1: Etanercept, Phase 1: Methotrexate, Phase 2: Optional ETN, SSZ, HCQ, MTX
- Where
- 33 sites in Argentina, Chile and 3 more
- Volunteers
- 429 people
- Sponsor
- Pfizer
Primary Immune Thrombocytopenia
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia…
- Trial name
- myOpportunITy1 (NCT04200456)
- Testing
- Rozanolixizumab
- Where
- 29 sites in United States, Bulgaria and 14 more
- Volunteers
- 33 people
- Sponsor
- UCB Biopharma SRL
Rheumatoid Arthritis
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra in patients with rheumatoid arthritis who have had an inadequate response (or were intolerant to)…
- Trial name
- NCT01579006
- Testing
- Tocilizumab
- Where
- 14 sites in Israel
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis (RA)
A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT03823378
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 30 sites in Belgium, Canada and 5 more
- Volunteers
- 97 people
- Sponsor
- AbbVie
Myasthenia Gravis
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
MG may be neonatal, congenital, or autoimmune. Neonatal MG arises from transplacental transfer of ACh receptor antibodies from a mother with autoimmune MG to the fetus.
- Trial name
- NCT00424489
- Testing
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Arthritis, Juvenile Rheumatoid
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: Unknown adverse drug reactions (especially important adverse…
- Trial name
- NCT01412021
- Volunteers
- 375 people
- Sponsor
- AbbVie
Osteoarthritis, Rheumatoid Arthritis
Reciprocating Medical Devices - a Study of a New Safety Device
The study design is a randomized study to directly compare the performance and the outcome of syringe and needle procedures with a standard syringe or the new reciprocating procedure device (RDP), which is a type of safety…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Trauma, Thyroid Nodule
- Trial name
- RPD (NCT00651625)
- Testing
- Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001, conventional syringe - BD Ref 309604
- Where
- United States
- Volunteers
- 437 people
- Sponsor
- University of New Mexico
Multiple Sclerosis
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
The purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis
- Trial name
- IMPAMS (NCT01214317)
- Testing
- plasmapheresis
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Isfahan University of Medical Sciences
Type 1 Diabetes Mellitus
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
- Trial name
- NCT02516150
- Testing
- Ethanol, Glucagon
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.